Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million
Open original sourceLoading market dashboard
First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million
Open original source